Summary of Key Points Core Viewpoint - As of September 4, 60 stocks reached their 52-week highs, indicating a positive market trend with notable performances from specific companies such as Gaoshan Enterprises, Milan Station, and Yongyi International [1]. Group 1: 52-Week Highs - Gaoshan Enterprises (00616) achieved a closing price of 0.350 with a peak of 0.370, marking a high rate of 60.87% [1]. - Milan Station (01150) closed at 0.340, reaching a high of 0.360, with a high rate of 44.00% [1]. - Yongyi International (01218) had a closing price of 3.830 and a peak of 4.100, resulting in a high rate of 17.14% [1]. - Other notable stocks include: - Cheng Tian Jia He (01132) with a high rate of 16.49% [1]. - San Ye Cao Biotechnology - B (02197) with a high rate of 16.46% [1]. - Capital Financial Holdings (08239) with a high rate of 16.28% [1]. Group 2: 52-Week Lows - Wanma Holdings (02935) reached a low of 0.034, reflecting a decline of 25.00% [2]. - Rongyang Industrial (02078) had a closing price of 0.160, with a low of 0.069, indicating a drop of 15.85% [2]. - Energy International Investment (00353) closed at 0.295, reaching a low of 0.275, down by 12.70% [2]. - Other significant declines include: - Qianli Holdings (08367) with a drop of 12.00% [2]. - Yunkang Group (02325) with a decline of 10.71% [2]. - Wanwei International (00167) down by 7.41% [2].

Core Viewpoint - The recent volatility in the Hong Kong stock market has led to increased investor interest in certain small-cap stocks, particularly Energy International Investment Holdings (00353.HK), which has shown impressive financial performance despite its small size [1][3]. Financial Performance - Over the past twelve months, the company reported revenue of approximately HKD 152 million, while achieving a net profit of HKD 256 million, indicating a net profit significantly higher than revenue, a rarity among Hong Kong-listed companies [3]. - The company's price-to-earnings ratio (TTM) has dropped to below 1.5 times, reflecting a very low valuation, with a market capitalization maintained in the range of HKD 300 million to HKD 400 million [3]. - The earnings per share (EPS) for the fiscal year 2025 has risen to HKD 0.24, compared to HKD 0.056 in the same period of 2024, showcasing a multiple growth in profit levels within a year [3]. Investment Logic - Supporters argue that the company's core business linked to energy logistics has stable market demand, combined with the cash flow characteristics of its insurance brokerage business, providing a degree of defensiveness [4]. - Critics caution that the profit statement may include non-recurring income, suggesting that the true profitability could be overstated if one-time items are excluded [4]. - The company has low trading activity and limited institutional coverage, which results in low stock price elasticity, making its undervaluation more pronounced [4]. Business Overview - Energy International Investment Holdings transitioned its business focus from mineral resources to energy logistics and insurance around 2010, with its terminal and storage services primarily catering to the liquid chemical and oil-related industries [4]. - The company's operations are significantly influenced by international energy price fluctuations and regional demand, indicating a cyclical nature [4]. - The insurance brokerage business contributes stable cash flow, supplementing the overall profitability of the company [4]. Market Outlook - Overall, Energy International Investment Holdings is characterized as a small-cap stock with extremely low valuation, attracting attention due to its impressive profit data and low PE ratio [5]. - The market is generally awaiting further evidence to confirm the sustainability of its profits, which will be crucial for the company's valuation recovery [5]. - The company's ability to explore new growth avenues beyond its core business and maintain stable shareholder returns will be key factors influencing its long-term valuation [5].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 本月底法定/註冊股本總額： HKD 1,500,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算所有限公司 公司名稱: 能源國際投資控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00353 | 說明 | 能源國際投資 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 150,000,000,000 | HKD | | 0.01 | HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本 ...

Core Viewpoint - Jinfang Pharmaceutical has officially passed the Hong Kong Stock Exchange hearing, indicating the upcoming addition of another 18A new stock to the Hong Kong market, which has seen strong performance from 18A companies this year [1] Company Overview - Jinfang Pharmaceutical was established in 2017, focusing on the development of innovative therapies for tumors, autoimmune, and inflammatory diseases. The company has completed multiple rounds of financing before its IPO, with notable investors including Shenzhen Capital Group, DCM, and Huagai Capital [1] Pipeline and Product Layout - The company has established a research pipeline consisting of eight candidate drugs, five of which are in clinical stages. Key products include GFH925 and GFH375. GFH925 is a self-developed drug approved for clinical use in 2021 and is expected to be commercially available in China in 2024. It is the first KRAS G12C inhibitor in China and the third globally, aimed at treating advanced non-small cell lung cancer [4][5] - GFH375 is an oral small molecule inhibitor targeting KRAS G12D mutations and is currently in Phase II clinical trials. The company anticipates that GFH925 may enter the medical insurance negotiation directory by 2026, with a patent protection period exceeding 15 years [4] Commercialization and Partnerships - Jinfang Pharmaceutical's core products heavily rely on external partnerships for commercialization. The company has signed exclusive licensing agreements with various firms, including Innovent Biologics and Merck KGaA. For instance, the clinical development and commercialization rights of GFH925 in Greater China have been transferred to Innovent Biologics, while Jinfang retains overseas rights [5] - This partnership model provides cash flow and research support but also diminishes the company's control over its core assets. The company acknowledges in its prospectus that future revenue will be influenced by the market performance of its partners, and any adjustments or poor execution of agreements could adversely affect its performance [5] Financial Status and R&D Investment - Financially, Jinfang Pharmaceutical is still in a loss phase, with projected revenues of 73.73 million yuan and 105 million yuan for 2023 and 2024, respectively, while net losses are expected to reach 508 million yuan and 678 million yuan. The losses are primarily due to substantial R&D investments and changes in the fair value of equity [6] - The company maintains R&D expenditures above 300 million yuan, with nearly 70 million yuan invested in the first four months of 2025 alone. The company emphasizes that sustained long-term investment is essential for advancing its pipeline and achieving commercialization [6] Shareholder Background and Financing History - The controlling shareholders of Jinfang Pharmaceutical include founding team members and an employee stock ownership platform, collectively holding approximately 25.23% of the shares. The founder, Lü Qiang, has extensive industry experience from previous executive roles in well-known pharmaceutical companies [7] - Since 2018, the company has completed multiple financing rounds, raising approximately 1.421 billion yuan. Investors include top-tier funds such as Honghui Capital and Northern Light Venture Capital, indicating strong market interest in Jinfang Pharmaceutical [7] - Currently, the company has seven self-developed products approved, with an additional twelve in Phase III clinical trials and twelve in Phase I/II stages, of which fifteen are global firsts or best-in-class. The company aims to become a leading innovative pharmaceutical enterprise through continuous R&D, building an international production system, and expanding its commercial network [7]

智通财经APP讯，能源国际投资(00353)发布公告，于2025年8月，外商独资企业接获由自然人登记股东 (即孙先生及占先生)、公司登记股东(即深圳绿合能)及营业公司联合发出的要求函件，要求函件要求外 商独资企业作出规定同意以将现时以自然人登记股东名义登记的营业公司70%股权转让予公司登记股 东。 以新结构性合约取代现有结构性合约并无对集团营运或财务状况产生任何重大不利影响。紧随股权转让 及订立新结构性合约后，外商独资企业将继续享有营业公司集团产生的70%经济利益，及营业公司集团 的财务业绩将继续由集团采用会计权益法入账。 经外商独资企业同意，股权转让已于2025年8月25日进行。于2025年8月25日，公司登记股东、自然人登 记股东、龙广、外商独资企业、营业公司及其他相关订约方订立新结构性合约(除变更订约方以及其他 相应及必要更改外，其条款及条件与现有结构性合约大致相同)，赋予外商独资企业等同于及╱或不逊 于现有结构性合约的权利及权力，并完全取代现有结构性合约。 ...

能源国际投资(00353)发布公告，于2025年8月，外商独资企业接获由自然人登记股东(即孙先生及占先 生)、公司登记股东(即深圳绿合能)及营业公司联合发出的要求函件，要求函件要求外商独资企业作出规 定同意以将现时以自然人登记股东名义登记的营业公司70%股权转让予公司登记股东。 经外商独资企业同意，股权转让已于2025年8月25日进行。于2025年8月25日，公司登记股东、自然人登 记股东、龙广、外商独资企业、营业公司及其他相关订约方订立新结构性合约(除变更订约方以及其他 相应及必要更改外，其条款及条件与现有结构性合约大致相同)，赋予外商独资企业等同于及╱或不逊 于现有结构性合约的权利及权力，并完全取代现有结构性合约。 以新结构性合约取代现有结构性合约并无对集团营运或财务状况产生任何重大不利影响。紧随股权转让 及订立新结构性合约后，外商独资企业将继续享有营业公司集团产生的70%经济利益，及营业公司集团 的财务业绩将继续由集团采用会计权益法入账。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 佈 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 ENERGY INTERNATIONAL INVESTMENTS HOLDINGS LIMITED 能源國際投資控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：353） 訂立新結構性合約 根 據 現 有 結 構 性 合 約 的 條 款，尤 其 是 根 據 獨 家 購 買 權 協 議 及 投 票 權 代 表 委 任 協 議，除 非 獲 得 外 商 獨 資 企 業 的 事 先 書 面 同 意，否 則 自 然 人 登 記 股 東 無 法 轉 讓 於 營 業 公 司 的 股 權。 於 二 零 二 五 年 八 月，外 商 獨 資 企 業 接 獲 由 自 然 人 登 記 股 東（即 孫 先 生 及 占 先 生）、公 司 登 記 股 東（即 深 圳 綠 合 能）及 營 業 公 司 聯 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 佈 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 ENERGY INTERNATIONAL INVESTMENTS HOLDINGS LIMITED 能源國際投資控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：353） 於二零二五年八月二十二日舉行之 股東週年大會之投票表決結果 附 註： 各 決 議 案 之 全 文 載 於 該 通 告。 由於超過50%票 數 贊 成 各 項 決 議 案，故 所 有 決 議 案 均 作 為 本 公 司 普 通 決 議 案 於 股 東 週 年 大 會 上 獲 正 式 通 過。 – 2 – 茲 提 述 能 源 國 際 投 資 控 股 有 限 公 司（「本公司」）日 期 均 為 二 零 二 五 年 七 月 二 十 八 日 的 通 函（「該通函」）及 股 東 週 年 大 會（「股東週年大會」）通 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 能源國際投資控股有限公司 第 1 頁 共 10 頁 v 1.1.1 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00353 | 說明 | 能源國際投資 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 150,000,000,000 | HKD | | 0.01 | HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 150,000,000,000 | HKD | | 0 ...

Core Viewpoint - Energy International Investment (00353) reported a significant decline in revenue for the fiscal year 2024-2025, while net profit saw a substantial increase, indicating a mixed financial performance [2]. Financial Performance - The company achieved a revenue of HKD 152 million, a year-on-year decrease of 37.38% [2]. - The net profit attributable to shareholders was HKD 256 million, reflecting a year-on-year increase of 393.04% [2]. - The net cash flow from operating activities was HKD 90.817 million, down 73.78% compared to the previous year [28]. - Basic earnings per share were HKD 0.2372, with an average return on equity of 22.57%, up 17.06 percentage points from the previous year [2][24]. Valuation Metrics - As of July 25, the company's price-to-earnings (P/E) ratio was approximately 1.54 times, the price-to-book (P/B) ratio was about 0.31 times, and the price-to-sales (P/S) ratio was around 2.6 times [2]. Business Segments - The company operates primarily in the oil and liquid chemical products terminal sector, providing leasing and logistics services, as well as trading agency services [11]. Cash Flow and Capital Structure - The net cash flow from financing activities was negative HKD 145 million, a decrease of HKD 259 million year-on-year [28]. - The net cash flow from investing activities was negative HKD 520 million, compared to HKD 53.391 million in the previous year [28]. Asset and Liability Changes - As of March 31, 2025, cash and cash equivalents decreased by 39.52%, while investment properties increased by 35.22% [36]. - Short-term borrowings decreased by 86.13%, while deferred tax liabilities increased by 72.94% [39]. - The current ratio was 5.57, and the quick ratio was 5.56, indicating strong liquidity [43].